Connect with us

Press Release

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia

Published

7 months ago

on

  • Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria

 

HONG KONG, China and WILMINGTON, Del. –1 April, 2024 –China Medical System Holdings Limited (“CMS” or the “Group”) and Incyte (Nasdaq:INCY) (“Incyte”) are pleased to announce that on 31 March 2024, that the Group, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), and Incyte entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory.

 

Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory.

 

CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.

 

“We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Herve Hoppenot, Chief Executive Officer, Incyte. “There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.”

 

Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that, “We expect that this collaboration will enhance CMS Skinhealth’s portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China. Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline ILUMETRI (tildrakizumab injection), original drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.”

 

The transaction is effective immediately upon the execution of the Collaboration and License Agreement.

 

About Povorcitinib

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Additionally, Phase 2 clinical studies of povorcitinib for PN, asthma and chronic spontaneous urticaria are also ongoing.

 

About Vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo.

 

It is estimated that there are approximately 14 million vitiligo patients in China and 6.5 million in the eleven Southeast Asian countries respectively. Non-segmental vitiligo patients account for approximately 85% of them[1]. Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 30[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo.

 

About Hidradenitis Suppurativa (HS)

HS is a chronic recurrent inflammatory skin condition characterized by the presence of painful inflammatory nodules, abscesses, ruptures, as well as the formation of sinus tracts and scarring. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS[3].

 

It is estimated that there are approximately 470 thousand HS patients in China, about 75% of whom are moderate to severe patients[4]. Additionally, it is estimated that there are approximately 13 thousand HS patients in the six Southeast Asian countries, comprising Thailand, Singapore, Malaysia, Philippine, Vietnam and Indonesia. HS has been included in the second batch of the Rare Disease List in China. Given the debilitating nature of condition, it can have a profoundly negative effect on patients’ quality of life. However, currently in China, there are no biologics or small molecule medicines approved by the National Medical Products Administration for the treatment of HS, creating an urgent need for effective therapeutic options[5].

 

About CMS Skinhealth

CMS’s Dermatology and Medical Aesthetic Business “CMS Skinhealth” regards dermatology prescription products as its core, and extends to dermatology-grade skincare products and light medical aesthetic products, continually optimizing full lifecycle skin-health management solutions, and gradually moving toward becoming “the largest and most professional skin-health management company in China “. Relying on its strong clinical development and commercialization advantages, CMS will realize the commercialization of povorcitinib in the Territory as soon as possible to meet the clinical needs of oral vitiligo drugs with efficacy and benefit relevant patients.

 

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

 

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Incyte Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether and when povorcitinib will be approved for use in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; whether and when CMS will bring povorcitinib to market in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; the potential of povorcitinib to treat patients with vitiligo, hidradenitis superativa or for any other indication; the potential for Incyte to receive royalties and payments from CMS for development and commercial milestones; and the potential for Incyte to broaden its ability to bring new medicines to patients in Asia and elsewhere, contain predictions, estimates and other forward-looking statements.

 

These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; Incyte’s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte’s products and the products of its collaboration partners; the acceptance of Incyte’s products and the products of its collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended December 31, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements.

 

CMS Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. This press release may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from this press release is expressly excluded.

 

Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Group assumes no obligation to update any forward-looking information contained in this press release. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

 

Contacts:

CMS

Investor Relations: ir@cms.net.cn

Incyte

Media: media@incyte.com

Investors: ir@incyte.com

 

 

Reference：

1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15. PMID: 25596811

2. Frisoli M, et al. Vitiligo: mechanisms of pathogenesis and treatment. Annu. Rev. Immunol. 2020;38(1):621-648

3. Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging topical and systemic JAK inhibitors in dermatology. Frontiers in immunology, 10, 2847

4. Prevalence of Acne Inversa (Hidradenitis Suppurativa) in China: A Nationwide Cross-Sectional Epidemiological Study

5. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

 

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Richy Media Revolutionizes PR with Advanced Newswire Publishing and Customized Distribution Solutions

Published

2 hours ago

on

October 18, 2024

By

Richy Media is an award-winning press release distribution and newswire publishing company that is transforming the way businesses connect with their target audiences. With a commitment to innovation and customer satisfaction, Richy Media offers a comprehensive suite of services designed to amplify brand messaging and achieve exceptional news outlets placements.

Richy Media stands out in the industry with its:

  • NewsWire Network: We have established strong relationships with major media outlets, journalists, and influencers across various industries, ensuring that your press releases reach the right audience.
  • Cutting-Edge Technology: Our platform leverages advanced technology to optimize press release distribution, tracking, and analysis, providing valuable insights into campaign performance.
  • PR Distribution Campaigns: We understand that every business is unique. Our team of experts works closely with clients to develop customized strategies that align with their specific goals and budgets.
  • Customer Support: We provide unparalleled customer support, guiding clients through every step of the process and ensuring a seamless experience.

“In today’s dynamic media world, PR communication is paramount,” says Karlo Bilal, Founder & CEO @ Richy Media. “We are passionate about growing businesses with media technology and expertise they need to share their stories and achieve their PR objectives.”

Richy Media offers a range of services, including:

  • Press Release Distribution: We ensure your press releases reach a wide audience through our extensive network of media outlets and online channels.
  • Newswire Publishing: We publish your press releases on Richy Media newswire, providing increased visibility and credibility.
  • Media Monitoring: We track media coverage and provide detailed reports, allowing you to measure the impact of your campaigns.
  • Content Creation: Our team of experienced writers can craft compelling press releases that capture the attention of journalists and readers.

About Our Company

Richy Media is a press release distribution and newswire publishing company dedicated to helping businesses achieve their communication goals. With a focus on innovation, customer satisfaction, and a results-oriented strategy, we empower businesses to connect with their target audiences and amplify their brand message.

Contact information:

Karlo Bilal, Founder & CEO @ Richy Media

pr@richymedia.com

https://richymedia.com

Operations: Worldwide

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

A Green Future Driven by Solar photovoltaic SPUSDT Solar PV Adoption

Published

2 hours ago

on

October 18, 2024

By

As the global climate crisis intensifies, more and more countries and regions recognize that promoting and adopting clean energy has become a key means of combating climate change. Among the various renewable energy technologies, solar photovoltaic (PV) stands out for its cost-effectiveness and environmental benefits, becoming a vital driver of the global energy transition. However, achieving global solar PV adoption requires not only technological advancements but also the establishment of industry standards, regulatory frameworks, and international cooperation. As a leading blockchain energy trading platform, SPUSDT is dedicated to promoting the global adoption of solar PV and providing innovative technical and regulatory solutions to ensure the sustainable development of the industry.

The Key to Global Adoption: Lowering Barriers and Enhancing Market Access

To achieve global solar PV adoption, the first challenge is to reduce market entry barriers. In traditional energy markets, the cost of participating in solar energy production and trading is often high, particularly for small and medium-sized enterprises (SMEs) and individual users. The complexity of installing solar systems and engaging in energy trading can be overwhelming. SPUSDT addresses these challenges through decentralized blockchain technology, significantly lowering these barriers. With SPUSDT, any individual or business can easily participate in solar energy trading, regardless of their generation capacity. They can directly connect with global consumers or investors through the platform, enabling swift and efficient energy transactions. This streamlined market entry mechanism not only reduces transaction costs but also improves energy efficiency, accelerating the widespread adoption of solar PV.

In addition, SPUSDT integrates with the USDT stablecoin to ensure price stability in energy transactions. This allows global users to avoid the volatility of the cryptocurrency market and secure more stable returns. This trading model attracts more investors into the solar PV market, further promoting the adoption and application of solar energy.

Establishing Industry Standards: Promoting Solar PV Standardization

In the global promotion of solar PV, establishing unified industry standards and norms is a crucial step. Solar system installation, operation, and maintenance must adhere to strict technical standards to ensure safe and efficient electricity generation. However, the global solar PV industry currently lacks consistent technical regulations, with different regions imposing varying installation standards and quality requirements. This inconsistency limits the widespread adoption of solar PV. SPUSDT actively promotes the establishment and dissemination of industry standards, aiming to create uniform regulations for the global solar PV market.

SPUSDT also plans to collaborate with international standardization organizations to drive the global unification of solar PV-related technical standards. For instance, the platform will work with bodies like the International Electrotechnical Commission (IEC) and the International Renewable Energy Agency (IRENA) to promote best practices in solar system installation, generation, transmission, and maintenance. This global standardization effort will help reduce market barriers and foster cross-border energy trading and cooperation.

International Regulation: Ensuring Compliance and Transparency in Solar PV Trading

As the solar PV market rapidly expands, international regulatory issues become increasingly important. The global adoption of solar PV requires more than technological breakthroughs; it also demands transparency and regulatory compliance in the market. To this end, SPUSDT implements multi-level international regulatory measures, ensuring that every transaction complies with relevant laws and regulations, thereby protecting market participants’ rights.

Firstly, SPUSDT collaborates closely with governments and regulatory bodies worldwide, ensuring its operations comply with local energy and financial regulatory frameworks. The platform has established a dedicated compliance team that monitors policy changes across different regions in real time. Based on the specific legal requirements of each country or region, the platform adjusts its operational processes accordingly. Whether in Europe, Asia, or North America, SPUSDT strictly adheres to local energy and financial regulations, ensuring that platform users can trade within a legal framework.

Moreover, the platform leverages the transparency and immutability of blockchain technology to create a robust audit and traceability system. Every transaction, every solar PV system’s generation data, and every energy delivery is meticulously recorded on the blockchain, ensuring that all transactions are open and transparent. This transparent record-keeping system not only helps users track the source of their energy but also provides regulators with powerful market oversight tools. Through these measures, SPUSDT ensures the compliance and transparency of global solar PV trading, fostering the healthy development of the market.

Promoting International Cooperation: Facilitating Global Solar Energy Connectivity

To further accelerate the global adoption of solar PV, SPUSDT actively promotes international cooperation and collaboration. The platform utilizes cross-chain technology to seamlessly connect with other blockchain networks, enabling users from different countries and regions to engage in cross-border energy trading freely. Cross-chain technology breaks down traditional geographic barriers in energy markets and fosters global energy market connectivity, providing the technical support necessary for the global expansion of solar PV.

Additionally, SPUSDT plans to collaborate with multiple international clean energy funds, green investment institutions, and multilateral development banks to advance project financing and development for solar PV. Through these partnerships, the platform will attract more international investors to participate in the construction of large-scale solar PV projects worldwide. This international cooperation will not only accelerate the adoption of solar PV but also contribute significantly to achieving global sustainable development goals.

The launch of the SPUSDT platform marks not only a significant innovation in solar energy trading but also a critical step toward global solar PV adoption. By lowering market entry barriers, establishing unified industry standards, enhancing international regulatory cooperation, and fostering global market connectivity, SPUSDT provides comprehensive technical and policy support for the future development of the global clean energy market. As solar PV continues to be widely adopted around the world, SPUSDT is poised to become a driving force in the global renewable energy market, contributing to the realization of a green future.

Contact name: Saif

Company name: HRG

Website https: https://hrginvestment.com/

Country: UAE

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ZainTECH and Urbi Forge Strategic Partnership to Drive Geospatial Innovation across the MENA Region

Published

2 hours ago

on

October 18, 2024

By

  • The agreement was signed at GITEX Global 2024, to integrate Urbi’s refined geospatial insights with ZainTECH’s digital expertise
  • Partnership will  see the companies drive substantial improvements across key sectors including environmental sustainability, transportation, real estate development, security, risk management, and healthcare.

Nahla Elbanhawy – MEA Business Development Manager, Urbi, Youssef Hindy – Account Manager, Urbi, Mohammed Al Beloushi – Deputy CEO, Urbi, Alexander Sysoev – Co-Founder, Urbi, Andrew Hanna – CEO, ZainTECH, Pavel Mochalkin – CEO, Urbi Maatje Rencken –  VP Digital Solutions, ZainTECH, Amr Elenein – CCO, Urbi

Dubai, United Arab Emirates, 18th October 2024, ZainTECH, the integrated digital solutions provider of Zain Group today announced signing a  memorandum of understanding (MoU) with Urbi,  the developer of a cutting-edge geo-platform that integrates all the necessary data, algorithms, and tools to address challenges in mapping, location data, navigation, and spatial analysis, aimed at merging Urbi’s refined geospatial insights with ZainTECH’s digital expertise. 

Signed at GITEX Global in Dubai, where ZainTECH is an exhibitor for the second year in-a-row, and has a stand located in Hall 21, Stand C10, the partnership will provide the region with innovative geospatial solutions as ZainTECH looks to leverage its innovative digital solutions with Urbi’s specialized geospatial capabilities. Urbi’s expertise in geospatial services, combined with ZainTECH’s robust digital solutions, will enhance ZainTECH’s ability to tackle complex regional issues by integrating sophisticated mapping and analytics with cutting-edge digital technology.

Andrew Hanna, CEO of ZainTECH commented, “Urbi has numerous compelling capabilities that could support the further upliftment of some of our solutions. The ability to have the highest quality geospatial information available in a secure, quick, and reliable manner is an extremely valuable proposition, and we look forward to integrating such resources across our portfolio of offerings.”

Pavel Mochalkin, CEO of Urbi said, “Partnering with ZainTECH marks a significant milestone for Urbi as we strive to redefine geospatial innovation in the MENA region. This collaboration will enhance our capacity to leverage geospatial technology, significantly expanding the opportunities for businesses and governments to experience the benefits of our services. Ultimately, it will help bring-to-life our vision of transforming everyday scenarios into a winning, transformative reality.” 

The collaboration is also set to leverage ZainTECH’s capabilities in emerging technologies such as AI, blockchain, and IoT, which are crucial for developing next-generation geospatial solutions. This aligns with Urbi’s focus on using innovative technologies to enhance spatial data utilization and smart city applications. Thus together, the companies are looking to drive substantial improvements across key sectors such as environmental sustainability, transportation, real estate development, security, risk management, and healthcare

With a joint commitment to environmental sustainability, ZainTECH’s involvement in smart building technologies and sustainability assessments, combined with Urbi’s focus on sustainable urban and environmental planning, will enhance their capacity to deliver eco-friendly and efficient solutions.

During GITEX Global, Jad Hammoud ZainTECH Vice-President – GTM, Alliances and Revenue Marketing and Patrik Eriksson, Director of Data Technology & Delivery, presented a compelling overview at Urbi’s stand, revealing the innovative digital strategies planned for the region. 

Both ZainTECH and Urbi look forward to implementing their joint strategies and witnessing the transformative impact of their solutions. 

About ZainTECH

ZainTECH is a regional integrated digital solutions provider, unifying Zain Group’s ICT assets to offer a unique value proposition of comprehensive digital solutions and services under one roof. The company is positioned to drive the transformation of enterprise and government customers in the MENA region by providing a center of excellence and managed solutions across the ICT stack, including cloud, cybersecurity, big data, IoT, AI, smart cities, drones and robotics, and emerging technologies.

ZainTECH leverages Zain’s global reach, unique regional footprint, and infrastructure across its operations in Kuwait, Saudi Arabia, Bahrain, Jordan, Iraq, and the United Arab Emirates, as well as in other key markets in the Middle East.

ZainTECH forms a key pillar in the evolution of Zain’s core telecom business to maximize value and build on the company’s many strengths to selectively create and invest in growth verticals beyond standard mobile services. This ultimately supports Zain’s vision of becoming a leading ICT and digital lifestyle provider.

For more information, please visit www.zaintech.com

About Urbi

Urbi is a global leader in geo-intelligence, providing cutting-edge solutions for smart cities, urban planning, and navigation. With a focus on data accuracy and innovation, Urbi empowers governments and organizations to make informed decisions and optimize urban infrastructure. To learn more, please visit www.urbi.ae

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us